Sunshine Biopharma, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SBFM research report →
About the company
Sunshine Biopharma, Inc. operates as a pharmaceutical entity and a provider of nutritional supplements, primarily dedicating its efforts to the research and development of novel anticancer therapies. A key pipeline candidate is Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin, designed to combat a broad spectrum of malignancies, including leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, and liver cancers.
- CEO
- Steve N. Slilaty
- IPO
- 2022
- Employees
- 52
- HQ
- Pointe-Claire, QC, CA
Price Chart
- Market Cap
- $1.06M
- P/E
- -0.02
- P/S
- 0.03
- P/B
- 0.05
- EV/EBITDA
- 0.91
- Div Yield
- 0.00%
- Gross Margin
- 32.49%
- Op Margin
- -12.90%
- Net Margin
- -17.01%
- ROE
- -25.58%
- ROIC
- -20.57%
- Revenue
- $36.31M · 4.11%
- Net Income
- $-5,975,352 · -16.39%
- EPS
- $-14.40 · 80.33%
- Op Income
- $-4,478,782
- FCF YoY
- 62.93%
- 52W High
- $24.30
- 52W Low
- $2.00
- 50D MA
- $5.14
- 200D MA
- $11.48
- Beta
- 1.31
- Avg Volume
- 1.62M
Get TickerSpark's AI analysis on SBFM
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 14, 26 | NATAN DAVID | other | 100,000 |
| Jan 13, 25 | Roy Michel | other | 0 |
| Mar 4, 24 | Slilaty Steve N. | buy | 100,000 |
| Feb 8, 24 | Slilaty Steve N. | buy | 20,000 |
| Jan 26, 24 | Beaudoin Marc | other | 0 |
| Nov 30, 22 | Sebaaly Camille | buy | 30,000 |
| Oct 20, 22 | Chamoun Malek | other | 0 |
| Jun 3, 22 | Sebaaly Camille | buy | 25,000 |
| Feb 18, 22 | Slilaty Steve N. | sell | 990,000 |
| Feb 10, 22 | NATAN DAVID | other | 0 |
Our SBFM coverage
Recent articles, reports, and earnings notes.
No research on SBFM yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SBFM report →Similar companies
Peers in the same neighborhood.